Data on Endocyte, Inc.'s Vintafolide and Etarfolatide to be Presented at the 3rd European Lung Cancer Conference

WEST LAFAYETTE, Ind., April 20, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that previously reported data on vintafolide (EC145), Endocyte’s lead drug candidate and etarfolatide (EC20), Endocyte’s diagnostic imaging agent, will be presented at the 3rd European Lung Cancer Conference in Geneva, Switzerland.